Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.68 |
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | FNTA | P49354 | 1/20 | 0.64 |
| ▸ | FNTB | P49356 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468399 | 1.00 | MEN1 (0.68) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL29407882 | 0.85 | MAPT (0.72) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21479833 | 0.85 | MAPT (0.72) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9531242 | 0.85 | MEN1 (0.62) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL29350750 | 0.84 | MEN1 (0.75) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL3448734 | 0.84 | MAPT (0.70) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL7887240 | 0.84 | MEN1 (0.75) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| Indole-3-Acetic Acid SCHEMBL26344 | 0.84 | MEN1 (0.75) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL4856078 | 0.83 | MEN1 (0.60) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL27760596 | 0.83 | MEN1 (0.65) | MEN1KMT2AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4423178-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2024-09-04 | — | — | EP | claimed |
| WO-2023073536-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2023-05-04 | — | — | WO | claimed |
| US-20250214996-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | CURIA GLOBAL, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4525865-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | Olema Pharmaceuticals, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4423178-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2024-09-04 | — | — | EP | disclosed |
| EP-4366734-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Olema Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023225354-A1 | CRYSTALLINE FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | OLEMA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4271682-A1 | METHOD OF SYNTHESIZING INDOLE COMPOUNDS | 1280225 B.C. Ltd. (CA) | 2023-11-08 | — | — | EP | disclosed |
| CN-116964049-A | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023073536-A1 | METHOD AND COMPOSITION FOR REDUCING SOLVENT RELEASE FROM, AND REDUCING ODOR OF, AGROCHEMICAL FORMULATIONS | ADAMA MAKHTESHIM LTD. (IL) | 2023-05-04 | — | — | WO | disclosed |
| CN-112679495-B | Estrogen receptor modulators | 里科瑞尔姆IP控股有限责任公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023283329-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | OLEMA PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4114391-A1 | METHODS OF TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES | Olema Pharmaceuticals, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022140844-A1 | METHOD OF SYNTHESIZING INDOLE COMPOUNDS | 1280225 B.C. LTD. (CA) | 2022-07-07 | — | — | WO | disclosed |
| EP-3993785-A1 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS | Olema Pharmaceuticals, Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214996-A1 | SALTS AND SOLID FORMS OF AN ESTROGEN RECEPTOR ANTAGONIST | ESR1, ESR2, ESRRA | MEN1 3962/4885KMT2A 1889/4885MAPT 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.